起始增量血液透析与标准血液透析及腹膜透析患者的结局比较
单中心回顾性分析313例2013年1月至2020年12月起始透析的成人,其中234例起始血液透析(166例标准每周三次血透、68例增量血透)、79例腹膜透析。增量血透较标准血透生存改善(HR 0.49,95%CI 0.26-0.93,P=0.029),腹膜透析生存相似;起始模式与1年住院天数无显著相关。
要点
- 增量血透较标准血透生存改善(HR 0.49,95%CI 0.26-0.93,P=0.029)。
- 腹膜透析与标准血透生存相似,起始模式与1年住院天数无显著相关。
- 68例增量血透中45例平均9.8±9.1个月后转为标准血透,持续增量者糖尿病更少(P=0.007)。
核心结论
- 增量血透适用于 selected 起始透析患者,可在转为标准血透前维持相当时间,糖尿病为风险因素。
- 起始增量血透较标准血透或腹膜透析与生存改善相关,但1年住院天数相似。
- 作者认为需等待随机对照试验结果后再大规模实施增量血透方案。
研究设计与样本
- 单大学中心前瞻性 assembled 队列的回顾性分析,纳入2013年1月至2020年12月所有起始透析的成人。
- 共313例,234例起始血透(166例标准每周三次血透、68例增量血透),79例腹膜透析。
主要发现
- 平均随访33.1±30.8个月,124例(39.6%)死亡。
- 增量血透较标准血透生存改善(HR 0.49,95%CI 0.26-0.93,P=0.029),腹膜透析与标准血透生存相似。
- 起始肾脏替代治疗模式与1年住院天数无显著相关。
- 研究结束时10例仍在增量血透,45例平均9.8±9.1个月后转为标准血透;持续增量血透者糖尿病更少(P=0.007)。
临床怎么用
- 作者认为增量血透适用于 selected 起始透析患者,可在转为标准血透前维持相当时间,糖尿病为风险因素。
- 作者认为需等待随机对照试验结果后再大规模实施增量血透方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Residual kidney function is considered better preserved with incremental haemodialysis (I-HD) or peritoneal dialysis (PD) as compared with conventional thrice-weekly HD (TW-HD) and is associated with improved survival. We aimed to describe outcomes of patients initiating dialysis with I-HD, TW-HD or PD. METHODS: We conducted a retrospective analysis of a prospectively assembled cohort in a single university centre including all adults initiating dialysis from January 2013 to December 2020. Primary and secondary endpoints were overall survival and hospitalization days at 1 year, respectively. RESULTS: We included 313 patients with 234 starting on HD (166 TW-HD and 68 I-HD) and 79 on PD. At the end of the study, 10 were still on I-HD while 45 transitioned to TW-HD after a mean duration of 9.8 ± 9.1 months. Patients who stayed on I-HD were less frequently diabetics (P = .007). Mean follow-up was 33.1 ± 30.8 months during which 124 (39.6%) patients died. Compared with patients on TW-HD, those on I-HD had improved survival (hazard ratio 0.49, 95% confidence interval 0.26-0.93, P = .029), while those on PD had similar survival. Initial kidney replacement therapy modality was not significantly associated with hospitalization days at 1 year. CONCLUSIONS: I-HD is suitable for selected patients starting dialysis and can be maintained for a significant amount of time before transition to TW-HD, with diabetes being a risk factor. Although hospitalization days at 1 year are similar, initiation with I-HD is associated with improved survival as compared with TW-HD or PD. Results of randomized controlled trials are awaited prior to large-scale implementation of I-HD programmes.
引用
- Jaques DA, Ponte B, Haidar F, et al. Outcomes of incident patients treated with incremental haemodialysis as compared with standard haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2022. PMID: 35731591. doi:10.1093/ndt/gfac205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。